Abuse of ecstasy and related designer-drugs;Abusus von Ecstasy und verwandten Designer-Drogen

Anasthesiologie und Intensivmedizin

Volumn 38, Issue 10, 1997, Pages 517-530

  Freye, E ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE   (Germany)

Author keywords

amphetamines; dehydration; poisoning; substance abuse

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADDICTION; ALCOHOL ABUSE; DEHYDRATION; DRUG ABUSE; DRUG ACTIVITY; DRUG EFFECT; DRUG TOXICITY; GERMANY; HUMAN; REVIEW; RISK ASSESSMENT;

EID: 0030668692     PISSN: 01711814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Ali SF, Newport GD, Scallet AC, Binienda Z, Ferguson SA, Bailey JR, Paule MG, Slikker WJ: Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol 15 (1993) 91.
2. Ames D, Wirshing WC: Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome - a possible link. J Am Med Assoc 268 (1992)1505.
3. Barret R, Taylor GT: "Ecstasy" ingestion: a case of severe complication. J Royal Soc Med 86 (1993) 233.
4. Beck J: The popularization and resultant implications of a recently controlled psychoactive substance. Contemp Drug Probl 13 (1986) 1.
5. Beck J, Morgan P: Designer drug confusion: a focus on MDMA. J Drug Edu 16 (1986) 267.
6. Chadwick IS, Curry PD, Linsley A, Freemont AJ, Doran B: Ecstasy, 3,4-methylenedioxyamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 84 (1991) 371.
7. Cooper JA, Bloom FE, Roth RH: The biochemical basis of neuropharmacology. 6ed.Oxford University Press. Oxford 1991
8. Dowling G.P, McDonough ET, Bost RO: "Eve" and "Ecstasy": A report of five deaths with the use of MDEA and MDMA. JAMA 257 (1987) 1615.
9. Fahal IH, Sallomi DF, Yaqoob M, Bell GM: Acute renal failure after ecstasy. Brit Med J 305 (1992) 29.
10. Freye, E: Akute Lebensbedrohliche Zustände - Symptome und erste therapeutische Maßnahmen. Zuckschwerdt. München, Bern, Wien, San Francisco 1990
11. Freye E: Designer-Drogen. Opioide aus der Drogenküche der Untergrundchemiker. DIA-GM 19 (1992) 1627.
12. Ginsberg MD, Henzman M, Schmidt-Novara WW: Amphetamine intoxication, with coagulopathy, hyperthermia and reversible renal failure. Ann Int Med 73 (1970) 81.
13. Gledshill MD, Moore DF, Bell D, Henry JA: Subarachnoid haemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiat 56 (1993) 1036.
14. Greer G: Using MDMA in psychotherapy. Advances 2 (1985) 57.
15. Grob C, Bravo G, Walsh R: Second thoughts on 3,4-methylenedioxy-methamphetamine (MDMA) neurotoxicity. Arch Gen Psychiatry 47 (1990) 288.
16. Henry JA, Jeffreys KJ, Dawling S: Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ectasy") Lancet 340 (1992) 384.
17. Henry JA, Jeffrys KJ, Dawling S: Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340 (1992) 384.
18. Hiramatzu M, Kwnagi Y, Unger SE, Cho AK: Metabolism of methylenedioxy-methamphetamine: formation of dihydroxymeth-amphetamine and a quinone identified as its glutathione. J Pharmacol Expt Ther 254 (1990) 521.
19. Hooft PH, van de Voorde HP: Reckless behaviour related to the use of 3,4-methylenedioxymethamphetamine (ecstasy). apropos of a fatal accident during car-surfing. Int J Legal Med 106 (1994) 328.
20. Kendrick WG, Hull AR, Knochel JP: Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Int Med 86 (1977) 381.
21. Kovar KA, Haerer M. Synthetische Suchtstoffe der 2. Generation (sog. Designer Drugs). 3. Mitteilung. Pharm Unserer Zeit 23 (1994) 52.
22. Kovar KA, Rosch C, Rupp A, Hermle L: Synthetische Suchtstoffe der 2.Generation (sog. Designer Drugs). Vol. 3. VGH Verlagsgesellschaft. Weinheim 1990
23. Lim HK, Foltz RL: Identification of metabolites of 3,4-methylenedioxy-methamphetamine in human urine. Chem Res Toxicol 2 (1989) 142.
24. Liester M, Grob CS, Bravo HL, Walsh, RN: Phenomenology and sequelae of 3,4-MDMA use. J Nerv Ment Dis 180 (1992) 345.
25. Logan AS, Stickle B, O'Keefe N. Survival following "Ecstasy" ingestion with a peak temperature of 42 degrees. Anaesthesia 48 (1993) 1017.
26. Lyon RA, Glennon RA, Titeler M: 3,4-Methylenedioxyamphetamine (MDMA): stereoselective interaction at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 88 (1986) 525.
27. Manchanda S, Connolly MJ: Cerebral infarction in association with Ecstasy abuse. Postgrad Med J 69 (1993) 874.
28. Maxwell DL, Polkey MI, Henry JA: Hyponatraemia and catatonic stupor after taking "ecstasy". Br Med J 307 (1993) 1399.
29. McCann UD, Ricaurte GA: MDMA ("ecstasy") and panic disorder; induction by a single dose. Biol Psychiat 32 (1992) 950.
30. McCann UD, Ricaurte GA: Reinforcing subjective effects of (±)3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic action: clinical evidence. J Clin Psychopharmacol 13 (1993) 214.
31. McGlothlin WH, Arnold DO: LSD revisited: A ten-year follow-up of the medical LSD use. Arch Gen Psychiat 25 (1971) 35.
32. McGuire P, Fahy T: Chronic paranoid psychosis after misuse of MDMA ("ecstasy"). Br Med J 302 (1991) 697.
33. Naranjo C: MDMA: The drug of analysis. Ballantine Books. New York 1973
34. Nichols DE: Differences between the mechanims of action of MDMA, MBDB and the classic hallucinogens. Identification of a new class: Entactogens. J Psycho Drugs 18 (1986) 305.
35. Pallanti S, Mazzi D: MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiat 32 (1992) 91.
36. Paris JM, Cunningham KA: Lack of neurotoxicity after inter-raphe microinjections of MDMA ("ecstasy"). NIDA Res Monogr 105 (1991) 333.
37. Picard-Maureau P: Drogen und Drogenscreening. MTA 12 (1995) 986.
38. Poklis A, Mackell MA, Drake WK: Fatal intoxication from 3,4-methylenedioxyamphetamine. J Forensic Sci 24 (1979) 70.
39. Price LH, Ricaurte GA, Krystal JH, Henninger GR: Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymeth-amphetamine (MDMA) users. Arch Gen Psychiatry 46 (1989) 20.
40. Rattray M: Ecstasy: Towards an understanding of the biochemical basis of the actions of MDMA. Essay Biochem 26 (1991) 7.7.
41. Ricaurte GA, Forno LS, Wilson MA, DeLanney L, Irwin I, Molliver ME, Langston JW: (±)3,4-methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 260 (1988) 51.
42. Ricaurte GA, Matello AL, Katz JL, Martello MB: Long lasting effects of (±)-3,4-methylenedioxyamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261 (1992) 616.
43. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C: Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals: neurochemical and anatomical evidence. Science 229 (1985) 986.
44. Rothwell PM, Grant R: Cerebral venous sinus thrombosis induced by ecstasy. J Neurol Neurosurg Psychiatry 56 (1985) 1035.
45. Rudnick G, Wall SC: The molecular mechanism of "ecstasy" 3,4-methylenedioxy-methamphetamine (MDMA): serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89 (1992) 1817.
46. Rupp A, Kovar KA, Beuerle G: A new pharmacophoric model for 5-HT reuptake inhibitors: differentiation of amphetamine analogues. Pharm Acta Helv 68 (1994) 253.
47. Satchell SC, Connaughton M: Inappropriate antidiuretic hormone secretion and extrem rises in serum creatinine following MDMA ingestion. Br J Hosp Med 51 (1994) 495.
48. Sounders N: Ecstasy. Ricco Bilger. Zürich 1994
49. Schmidt CJ: Neurotoxicity of the psychedelic amphetamine, MDMA. J Pharmacol Exp Ther 240 (1987) 1.
50. Screaton GR, Singer M, Cairns HS, Thrasher A, Cohen SL: Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet 339 (1992) 677.
51. Shulgin A, Nichols D. Characterization of three new psychomimetics. In: Stillmann R, Wilette R (Eds.) The Psychopharmacology of Halluzinogens, Pergamon. New York. pp. 74-82, 1978
52. Simpson DL, Rumack BH: Methylenedioxyamphetamine: Clinical description of overdose, death, and review of pharmacology. Arch Intern Med 141 (1981) 1507.
53. Singarajah C, Lavies NG: An overdose of ecstasay. A role for dantrolene. Anaesthesia 47 (1992) 686.
54. Steele TD, Nichols DE, Yim GWK: Stereochemical effects of 3,4-methylenedioxyamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]-monoamines into synaptosomes from different regions of the brain. Biochem Pharmacol 36 (1987) 2297.
55. Tehan B, Hardern R, Bodenham A: Hyperthermia associated with 3,4-methylenedioxymethamphetamine. Anaesthesia 48 (1993) 507.
56. White SR, Dnffy P, Kalivas PW: Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience 62 (1994) 41.
57. Yousif MY, Fitzgerald RL, Narasimhachari N, Rosecrans JA, Blanke RV, Gelnnon RA: Identification of 3,4-Methylenedioxymethamphetamine in rats. Drug Alcohol Depend 26 (1990) 127.